In November 2022, Rubius Therapeutics Inc (NASDAQ: RUBY) initiated a process to explore a range of strategic alternatives and planned to engage an investment bank to act as a strategic advisor. But ...
Rubius Therapeutics is led by CEO Dannielle Appelhans, who took the reins from Pablo Cagnoni, M.D., amid the tumult in November. (mbudley/iStock/Getty Images Plus) It’s the end of the road for Rubius ...
After several tireless days we have finished crunching the numbers from nearly 817 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which ...
Rubius Therapeutics went public in 2018 at a $2 billion valuation — the largest biotech stock market debut at that time. On Wednesday, the company — battered down to a market value of $15 million — ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results